Norah Sadek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Norah Sadek has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Aurelie Beroard
16 shared publicationsBenchun Miao
16 shared publications- Bradley Garman
Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
16 shared publications - Bradley Wubbenhorst
Division of Translational Medicine and Human Genetics and
16 shared publications - Chaoran Cheng
Department of Computer Science, New Jersey Institute of Technology, Newark, New Jersey, USA
16 shared publications Clemens Krepler
16 shared publications
Latest Publications
- Open Access
- 16 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1316
Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis
Background/Objectives: Chimeric antigen receptor T-cell therapy (CAR-T) has become a key treatment option for relapsed/refractory multiple myeloma (RRMM), but factors impairing T-cell fitness may diminish efficacy. Our exploratory analysis aimed to evaluate the impact of prior treatment with a selinexor-containing regimen on CAR-T outcomes for RRMM patients. Methods: Data for this retrospective cohort study were sourced from electronic medical records at two US academic centers. Kaplan–Meier estimates assessed duration of response (DOR), progression-free survival (PFS), and overall survival (OS), reported as medians with interquartile ranges (IQRs). Cox proportional hazards regression analyzed factors potentially associated with PFS and OS, reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Results: Among 45 patients exposed to selinexor before undergoing BCMA-directed CAR-T, median therapy line numbers for selinexor use and CAR-T were 7 and 9, respectively, with 24.4% receiving selinexor as part of bridging. At median follow-up of 68 months, median PFS and OS post CAR-T were 8.0 (IQR 3.1–39.5) and 35.9 (IQR 14.2–NR) months, respectively. Overall response rate to CAR-T was 89%, with a median DOR of 8.1 months (IQR 2.9–39.0). In our multivariable model, patients who received a selinexor-based regimen in the line of therapy preceding CAR-T showed a trend toward reduced risk of death (HR = 0.08; 95% CI 0.02–0.46) and/or disease progression (HR = 0.40; 95% CI 0.14–1.09). Conclusions: Prior selinexor exposure does not appear to compromise CAR-T outcomes in heavily pretreated RRMM, suggesting potential T-cell sparing. Our findings warrant larger, prospective studies to determine whether preemptive selinexor treatment can optimize CAR-T efficacy.
- 16 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1316
Open AccessImpact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis
Background/Objectives: Chimeric antigen receptor T-cell therapy (CAR-T) has become a key treatment option for relapsed/refractory multiple myeloma (RRMM), but factors impairing T-cell fitness may diminish efficacy. Our exploratory analysis aimed to evaluate the impact of prior treatment with a selinexor-containing regimen on CAR-T outcomes for RRMM patients. Methods: Data for this retrospective cohort study were sourced from electronic medical records at two US academic centers. Kaplan–Meier estimates assessed duration of response (DOR), progression-free survival (PFS), and overall survival (OS), reported as medians with interquartile ranges (IQRs). Cox proportional hazards regression analyzed factors potentially associated with PFS and OS, reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Results: Among 45 patients exposed to selinexor before undergoing BCMA-directed CAR-T, median therapy line numbers for selinexor use and CAR-T were 7 and 9, respectively, with 24.4% receiving selinexor as part of bridging. At median follow-up of 68 months, median PFS and OS post CAR-T were 8.0 (IQR 3.1–39.5) and 35.9 (IQR 14.2–NR) months, respectively. Overall response rate to CAR-T was 89%, with a median DOR of 8.1 months (IQR 2.9–39.0). In our multivariable model, patients who received a selinexor-based regimen in the line of therapy preceding CAR-T showed a trend toward reduced risk of death (HR = 0.08; 95% CI 0.02–0.46) and/or disease progression (HR = 0.40; 95% CI 0.14–1.09). Conclusions: Prior selinexor exposure does not appear to compromise CAR-T outcomes in heavily pretreated RRMM, suggesting potential T-cell sparing. Our findings warrant larger, prospective studies to determine whether preemptive selinexor treatment can optimize CAR-T efficacy.
- 4 November 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (6) , 1184-1195
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
The emergence of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of hematologic malignancies, including multiple myeloma (MM). Two BCMA‐directed CAR T‐cell products — idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) — have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti‐CD38 monoclonal antibody). Despite producing unprecedented response rates in an otherwise difficult to treat patient population, CAR T‐cell therapies are commonly associated with immune‐related adverse events (e.g., cytokine release syndrome and neurotoxicity), cytopenias, and infections. Moreover, many patients continue to exhibit relapse post‐treatment, with resistance mechanisms yet to be fully understood. Ongoing basic, translational, and clinical research efforts are poised to generate deeper insights into the optimal utilization of these therapies, improve their efficacy, minimize associated toxicity, and identify new target antigens in patients with MM.
- 4 November 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (6) , 1184-1195
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
The emergence of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of hematologic malignancies, including multiple myeloma (MM). Two BCMA‐directed CAR T‐cell products — idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) — have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti‐CD38 monoclonal antibody). Despite producing unprecedented response rates in an otherwise difficult to treat patient population, CAR T‐cell therapies are commonly associated with immune‐related adverse events (e.g., cytokine release syndrome and neurotoxicity), cytopenias, and infections. Moreover, many patients continue to exhibit relapse post‐treatment, with resistance mechanisms yet to be fully understood. Ongoing basic, translational, and clinical research efforts are poised to generate deeper insights into the optimal utilization of these therapies, improve their efficacy, minimize associated toxicity, and identify new target antigens in patients with MM.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Movie S3 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S3 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Movie S4 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2)-BR cells treated with 6-thio-dG.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S4 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2)-BR cells treated with 6-thio-dG.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Movie S4 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2)-BR cells treated with 6-thio-dG.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S4 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2)-BR cells treated with 6-thio-dG.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Movie S5 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2)-CR cells treated with the control.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S5 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2)-CR cells treated with the control.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Movie S6 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2)-CR cells treated with 6-thio-dG.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S6 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2)-CR cells treated with 6-thio-dG.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Movie S2 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2) cells treated with 6-thio-dG.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S2 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Time-lapse imaging of A375(Fucci2) cells treated with 6-thio-dG.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma